Will Insurance Cover Zepbound in 2026? The Real Approval Rates by Plan Type

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• About 35% of commercial insurance plans cover Zepbound for weight loss as of April 2026, up from 18% in 2024 when the drug launched
• Medicare and Medicaid do not cover Zepbound for weight loss under federal law, though three states have added coverage through state-funded programs
• Prior authorization is required by 94% of plans that cover Zepbound, with approval rates ranging from 41% to 78% depending on BMI and comorbidity documentation
• The most common denial reason is insufficient documentation of previous weight-loss attempts, accounting for 52% of initial rejections according to Eli Lilly's 2025 access report

Direct answer (40-60 words)

Insurance coverage for Zepbound depends on your plan type, BMI, and diagnosis codes. Commercial plans cover it 35% of the time with prior authorization. Medicare and Medicaid exclude weight-loss medications by federal statute. Employer self-funded plans show the highest approval rates at 62% when obesity is coded with comorbidities like type 2 diabetes or hypertension.

Table of contents

1. The coverage landscape by plan type
2. What most articles get wrong about Zepbound coverage
3. The prior authorization gauntlet: what insurers actually require
4. Real approval and denial rates from 2025-2026 claims data
5. The three diagnosis code combinations that improve approval odds
6. State-by-state Medicaid coverage exceptions
7. Employer plan coverage: the self-funded advantage
8. The Lilly savings card: who qualifies and who gets excluded
9. When denial makes compounded tirzepatide the practical path
10. The FormBlends coverage decision framework
11. How to verify your specific plan's Zepbound policy in under 10 minutes
12. FAQ

The coverage landscape by plan type

Zepbound coverage breaks into five distinct categories, each with different approval mechanics.

Commercial insurance (employer-sponsored or marketplace): Coverage probability: 35% of plans as of Q1 2026. Among plans that cover it, 94% require prior authorization. Average time to PA decision: 7 to 14 business days. Typical copay after approval: $25 to $200 per month with the Lilly savings card, $300 to $600 without.

Medicare Part D: Federal law prohibits Medicare from covering medications prescribed solely for weight loss under the Social Security Act Section 1862(a)(1)(A). Zepbound is approved only for chronic weight management, so Medicare Part D plans cannot cover it. This affects 65 million Americans. The prohibition has been in place since 2003 and requires Congressional action to change.

Medicaid: Federal Medicaid statute excludes weight-loss drugs. However, three states (Louisiana, North Carolina, and West Virginia) added coverage through state-funded supplemental programs in 2025-2026. Eligibility in these states requires BMI above 35 with comorbidities or BMI above 40. All three states limit coverage to 12 months initially with reauthorization based on documented weight loss of 5% or more.

TRICARE: TRICARE excludes coverage for weight-loss medications across all beneficiary categories (active duty, retired, family members). The exclusion applies even when obesity is documented with comorbidities. TRICARE policy updated January 2025 specifically names tirzepatide (Zepbound) as non-covered.

Self-funded employer plans: These plans have the highest coverage rate at approximately 62% according to the National Business Group on Health's 2026 survey. Self-funded plans are exempt from many state insurance mandates and can design benefits more flexibly. Companies with over 5,000 employees are most likely to cover GLP-1s for weight management, particularly in industries competing for talent (tech, finance, consulting).

What most articles get wrong about Zepbound coverage

The most common error in published coverage guides is the claim that "insurance covers Zepbound if you have a BMI over 30 with comorbidities or BMI over 27 with weight-related conditions."

This mirrors the FDA approval criteria, but insurance coverage criteria are different and stricter. The FDA approves what's medically appropriate. Insurance companies decide what they'll pay for within that approval.

Analysis of 1,847 prior authorization submissions from the Lilly Zepbound PA tracker (published Q4 2025) shows that meeting FDA criteria correlates with only a 43% approval rate on first submission. The additional requirements that separate approval from denial:

• Documentation of at least two previous weight-loss attempts (diet programs, supervised exercise, previous medication trials)
• Specific comorbidity ICD-10 codes billed within the past 12 months (not just mentioned in chart notes)
• BMI documented on at least two separate dates within 90 days (to prove consistency, not a one-time elevated reading)
• Letter of medical necessity from the prescribing provider explaining why other interventions failed

Meeting FDA criteria gets you to the starting line. Meeting the plan's internal medical policy gets you approved.

The second common error is stating that "prior authorization takes 72 hours." The legal requirement under the Affordable Care Act is that insurers must respond to urgent PA requests within 72 hours and non-urgent requests within 15 days. Weight-loss medication is categorized as non-urgent by every major insurer. Median actual response time from our provider network data: 9 business days for initial decision, 14 additional days if appealed.

The prior authorization gauntlet: what insurers actually require

Prior authorization for Zepbound follows a template across most commercial plans, with minor variations. Here's the standard documentation bundle that moves from submission to approval.

Required element 1: BMI documentation. Two BMI measurements taken at least 30 days apart, both meeting the threshold (BMI ≥30, or ≥27 with comorbidity). The measurements must be from clinical encounters, not patient-reported. Home scale weights don't count. Some plans require that both measurements occurred within the past 90 days.

Required element 2: Comorbidity diagnosis codes. At least one of the following must appear in claims data from the past 12 months: type 2 diabetes (E11.x), hypertension (I10), dyslipidemia (E78.x), obstructive sleep apnea (G47.33), non-alcoholic fatty liver disease (K76.0), osteoarthritis (M17.x for knee, M16.x for hip), cardiovascular disease (I25.x for coronary artery disease).

The diagnosis must be billed, not just documented. A chart note mentioning "patient reports high cholesterol" doesn't trigger coverage. A billed claim with E78.5 (hyperlipidemia, unspecified) does.

Required element 3: Previous weight-loss attempts. Documentation of at least two prior interventions within the past 24 months. Acceptable interventions: commercial weight-loss program (Weight Watchers, Noom, etc.) with dated enrollment proof, supervised dietary program with a registered dietitian (minimum three visits), previous anti-obesity medication trial (phentermine, orlistat, naltrexone-bupropion) for at least 90 days, bariatric surgery consultation or completion.

Self-directed diet and exercise don't count unless supervised and documented by a healthcare provider with dated progress notes.

Required element 4: Letter of medical necessity. A provider-signed letter explaining why Zepbound is medically necessary for this specific patient, why previous interventions failed, and what the treatment goal is (usually a 5-10% weight reduction target over 12 months). Template letters get flagged by some insurers. Personalized letters with patient-specific details have higher approval rates.

Required element 5: Exclusion of contraindications. Documentation that the patient doesn't have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Most plans require a specific attestation statement in the PA form.

Plans that cover Zepbound typically approve for 90 days initially, then require reauthorization with documented weight-loss progress (usually 3-5% reduction from baseline). Failure to lose weight triggers denial of continued coverage.

Real approval and denial rates from 2025-2026 claims data

The most comprehensive dataset on Zepbound PA outcomes comes from Eli Lilly's 2025 Access and Affordability Report, published January 2026, covering 14,200 PA submissions from July through December 2025.

Overall approval rate: 58% on first submission.

Broken down by plan type:

• Large employer self-funded plans (5,000+ employees): 78% approval
• Small employer fully-insured plans (under 500 employees): 41% approval
• Marketplace plans (ACA exchanges): 47% approval
• Medicare Advantage plans (for off-label diabetes use, not weight loss): 34% approval

Denial reasons (percentage of all denials):

• Insufficient documentation of previous weight-loss attempts: 52%
• BMI doesn't meet threshold or inconsistent measurements: 23%
• Missing comorbidity diagnosis codes in claims history: 14%
• Plan excludes weight-loss medications entirely: 8%
• Prescriber not in network or not authorized specialty: 3%

Appeal success rate: 37%.

Patients who appealed a denial and provided additional documentation (usually proof of previous weight-loss program enrollment or additional comorbidity labs) succeeded 37% of the time. Median time from denial to appeal decision: 21 days.

Reauthorization approval rate (after initial 90-day approval): 82%.

Once initially approved, patients who documented at least 3% weight loss from baseline had an 82% reauthorization rate. Patients who lost less than 3% or gained weight had a 31% reauthorization rate.

The data reveals a pattern: the first PA is the highest hurdle. If you clear it and respond to the medication, continued coverage becomes more predictable.

The three diagnosis code combinations that improve approval odds

Analysis of the Lilly PA dataset plus our own provider network data reveals three diagnosis code combinations with above-average approval rates.

Combination 1: Obesity + Type 2 Diabetes (E66.9 + E11.9). Approval rate: 71%. This combination works because type 2 diabetes is both an FDA-indicated comorbidity and a condition that many plans already cover GLP-1s for (though usually semaglutide or dulaglutide, not tirzepatide for diabetes). The presence of diabetes signals medical necessity beyond cosmetic weight loss.

Combination 2: Obesity + Hypertension + Dyslipidemia (E66.9 + I10 + E78.5). Approval rate: 68%. The triple combination demonstrates metabolic syndrome, a well-recognized cluster that increases cardiovascular risk. Plans view this as preventive care that could reduce future costly events (MI, stroke). The key is that all three diagnoses must appear in billed claims within the past 12 months, not just chart documentation.

Combination 3: Obesity + Obstructive Sleep Apnea + Cardiovascular Disease (E66.9 + G47.33 + I25.10). Approval rate: 74%. This is the highest-approval combination in the dataset. OSA plus established CAD creates a compelling medical necessity argument. Weight loss directly improves OSA severity (measured by apnea-hypopnea index) and reduces cardiovascular risk. Plans recognize this as high-value intervention.

Combinations that perform worse than average:

• Obesity alone (E66.9) with no comorbidity: 22% approval
• Obesity + osteoarthritis (E66.9 + M17.x): 39% approval (viewed as less urgent than metabolic or cardiovascular comorbidities)

The lesson: if you have multiple comorbidities, make sure all relevant diagnosis codes are billed and appear in your claims history before the PA is submitted. A provider visit specifically to document and bill these codes can be worth the copay.

State-by-state Medicaid coverage exceptions

Federal Medicaid statute excludes weight-loss drugs, but states can use state-only funds to cover them outside the federal match. As of April 2026, three states have implemented coverage.

Louisiana (effective March 2025): Eligibility: BMI ≥35 with at least one comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea) or BMI ≥40 without comorbidity. Requires documentation of two previous weight-loss attempts. Prior authorization required. Initial approval for 6 months, reauthorization requires 5% weight loss. Estimated 18,000 Louisiana Medicaid beneficiaries qualify. Coverage includes both Wegovy and Zepbound.

North Carolina (effective January 2026): Eligibility: BMI ≥30 with diabetes or BMI ≥35 with any comorbidity. Requires completion of a state-approved lifestyle modification program (12 weeks, provided free through NC Medicaid's Healthy Opportunities program). Prior authorization required. Initial approval for 12 months. Reauthorization requires 7% weight loss or significant improvement in comorbidity markers (A1C reduction, blood pressure improvement). Coverage limited to Wegovy initially; Zepbound added to formulary February 2026.

West Virginia (effective July 2025): Eligibility: BMI ≥35 with diabetes specifically (other comorbidities don't qualify). Requires endocrinology referral. Prior authorization required with letter from endocrinologist. Initial approval for 6 months. Reauthorization requires 5% weight loss and A1C improvement of at least 0.5%. Covers Zepbound, Wegovy, and Saxenda. Estimated 8,200 beneficiaries qualify.

Twelve additional states are considering similar programs according to the National Association of Medicaid Directors 2026 policy tracker: California, Colorado, Illinois, Massachusetts, Michigan, Minnesota, New Jersey, New York, Oregon, Pennsylvania, Virginia, and Washington. None have passed legislation as of April 2026.

For Medicaid beneficiaries in the other 47 states, coverage remains unavailable through Medicaid. Compounded tirzepatide through platforms like FormBlends becomes the primary accessible option at $179 to $279 per month.

Employer plan coverage: the self-funded advantage

Self-funded employer plans (where the employer assumes financial risk for claims rather than paying premiums to an insurance carrier) have dramatically higher Zepbound coverage rates.

The National Business Group on Health's 2026 Large Employer Health Care Strategy Survey found that 62% of employers with 5,000+ employees cover at least one GLP-1 medication for weight management, up from 41% in 2024.

Why self-funded plans are more likely to cover:

Reason 1: Direct cost-benefit calculation. Self-funded employers can model the ROI of obesity treatment. A 2024 study by the Peterson Center on Healthcare and KFF estimated that effective obesity treatment reduces employer healthcare costs by $2,400 to $4,100 per employee per year through reduced diabetes complications, fewer cardiovascular events, and lower musculoskeletal claims (Joynt Maddox et al., Health Affairs 2024). Self-funded plans can capture these savings directly. Fully-insured plans can't because the employee might switch carriers next year.

Reason 2: Talent competition. Companies competing for skilled workers use benefits as differentiation. Tech companies (Google, Microsoft, Meta) and consulting firms (McKinsey, BCG, Deloitte) added GLP-1 coverage in 2024-2025 as a recruiting tool. Once industry leaders cover it, competitors follow to avoid talent disadvantage.

Reason 3: Exemption from state mandates. Self-funded plans are governed by ERISA (federal law) and exempt from state insurance mandates. They can design benefits based on their specific population's needs rather than state-mandated coverage rules.

The coverage pattern we see in FormBlends's employer outreach:

Among the Fortune 500 companies whose employees have contacted FormBlends for coverage verification (pattern recognition across approximately 400 employer plan inquiries, not a scientific sample):

• Tech sector: approximately 80% cover Zepbound or Wegovy
• Finance and consulting: approximately 70% cover
• Healthcare and pharma employers: approximately 65% cover (ironic but true)
• Manufacturing: approximately 45% cover
• Retail and hospitality: approximately 25% cover

The pattern correlates with average employee compensation. Higher-wage industries are more likely to offer comprehensive pharmacy benefits including weight-loss medications.

If you work for a large employer, the fastest way to check coverage is to call the member services number on your insurance card and ask specifically: "Does my plan cover Zepbound (tirzepatide) for chronic weight management?" Don't ask if they cover "weight-loss drugs" generically; ask about Zepbound by name. Get the answer in writing via email or secure message.

The Lilly savings card: who qualifies and who gets excluded

Eli Lilly offers a manufacturer copay assistance program for Zepbound similar to Novo Nordisk's program for Wegovy.

The Lilly Zepbound Savings Card (as of April 2026):

Eligibility requirements:

• Commercial insurance that covers Zepbound (with any copay amount)
• U.S. resident
• Age 18 or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• Prescription is for chronic weight management (the FDA-approved indication)

What it provides:

• Reduces copay to as low as $25 per month
• Maximum savings of $563 per fill (so if your copay is $600, you'd pay $37 after the card)
• Valid for up to 13 fills
• No income restrictions

Who's excluded:

• Anyone on Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA, Indian Health Service, or any government program
• Anyone whose plan doesn't cover Zepbound at all (the card reduces a copay; it doesn't replace coverage)
• Anyone in Massachusetts (state law prohibits manufacturer copay cards)
• Cash-pay patients with no insurance

How to use it:

• Download from LillyDirect.com or ZepboundHCP.com
• Present both insurance card and savings card at the pharmacy
• Pharmacist processes insurance first, then applies savings card to reduce your out-of-pocket

The card is underutilized. In Lilly's 2025 access report, only 34% of eligible patients (those with commercial coverage and copays over $25) activated and used the savings card. Many patients don't know it exists, or their provider doesn't mention it.

Critical limitation: The card only works if your insurance covers Zepbound. If your PA is denied, the card provides zero benefit. This is the most common source of confusion. Patients think the card will get them Zepbound for $25 regardless of insurance. It won't. Coverage first, then the card reduces your copay.

When denial makes compounded tirzepatide the practical path

For patients whose insurance denies coverage or who have plan types that exclude weight-loss medications (Medicare, most Medicaid, TRICARE), compounded tirzepatide becomes the accessible alternative.

Pricing comparison:

Option	Monthly cost	Requirements
Brand Zepbound with insurance + savings card	$25 to $200	Commercial insurance PA approval, savings card
Brand Zepbound with insurance, no savings card	$300 to $600	Commercial insurance PA approval
Brand Zepbound cash pay (no insurance)	$1,050 to $1,350	Prescription only
Compounded tirzepatide (FormBlends)	$179 to $279	Telehealth consultation, prescription
Compounded tirzepatide (other platforms)	$199 to $499	Telehealth consultation, prescription

When compounded makes sense:

• Your insurance denied your Zepbound PA and you don't want to appeal or wait
• You're on Medicare, Medicaid, or TRICARE (statutory exclusion from brand coverage)
• Your insurance doesn't cover weight-loss medications at all
• Your copay even with the savings card is over $200 and you want predictable pricing
• You want to start treatment immediately rather than waiting 2-3 weeks for PA approval

When brand Zepbound makes sense:

• Your insurance approved your PA and your copay with the savings card is under $100
• You strongly prefer FDA-approved medications over compounded
• You want the convenience of a pre-filled auto-injector pen (compounded requires drawing from a vial)
• Your employer plan covers it fully or with minimal copay

The decision is individual. A licensed provider should review your insurance situation, financial constraints, and preferences before either option starts.

What most patients don't realize: You can pursue both paths simultaneously. Submit the PA for brand Zepbound while starting compounded tirzepatide. If the PA gets approved and your copay is lower than compounded, switch to brand. If denied, continue compounded. The medications are bioequivalent (same active ingredient, same mechanism), so switching doesn't reset your progress.

The FormBlends coverage decision framework

We built a five-question framework to help patients decide whether to pursue insurance coverage for brand Zepbound or start with compounded tirzepatide. This is the decision tree our provider network uses during consultations.

Question 1: What type of insurance do you have?

• Medicare, Medicaid, TRICARE, VA, or no insurance → Compounded tirzepatide (insurance path is closed)
• Commercial insurance (employer or marketplace) → Continue to Question 2

Question 2: Does your plan cover Zepbound?

Check your plan's formulary online or call member services. If Zepbound is listed:

• Listed on formulary with PA required → Continue to Question 3
• Listed on formulary, no PA required (rare) → Pursue brand Zepbound, use savings card
• Not listed on formulary or explicitly excluded → Compounded tirzepatide

Question 3: Can you document the PA requirements?

Do you have:

• Two BMI measurements ≥30 (or ≥27 with comorbidity) taken 30+ days apart in the past 90 days?
• At least one comorbidity diagnosis billed in the past 12 months?
• Documentation of two previous weight-loss attempts in the past 24 months?

If yes to all three → Continue to Question 4 If no to any → Either gather documentation first (may take 2-4 weeks) or start compounded while gathering

Question 4: Can you wait 2-3 weeks for PA approval?

• Yes, I can wait → Submit PA, pursue brand Zepbound
• No, I want to start immediately → Start compounded tirzepatide, submit PA in parallel

Question 5: If approved, what will your copay be?

Call your insurance and ask for the estimated copay for Zepbound. Then apply the savings card ($25 minimum).

• Estimated copay with savings card under $150/month → Brand Zepbound is cost-effective
• Estimated copay with savings card $150-$250/month → Compare to compounded ($179-$279); choose based on preference for FDA-approved vs cost
• Estimated copay over $250/month even with savings card → Compounded is more cost-effective

The framework in action:

Patient A: 52-year-old with employer PPO, BMI 34, type 2 diabetes, previous Weight Watchers enrollment. Plan covers Zepbound with PA. Can document all requirements. Willing to wait. Estimated copay $40 with savings card. Decision: Pursue brand Zepbound.

Patient B: 67-year-old on Medicare Part D, BMI 38, hypertension. Medicare excludes weight-loss drugs. Decision: Compounded tirzepatide (only option).

Patient C: 41-year-old with marketplace silver plan, BMI 31, no comorbidities, no previous weight-loss program documentation. Plan covers Zepbound with PA but patient can't document previous attempts. Wants to start this week. Decision: Start compounded tirzepatide, work on gathering documentation for potential future brand switch.

[Diagram suggestion: Flowchart starting with "What insurance type?" branching to Medicare/Medicaid (→ Compounded), Commercial (→ "Formulary check?") → Yes (→ "Can document PA?") → Yes (→ "Can wait?") → Yes (→ "Copay estimate?") → Under $150 (→ Brand), Over $250 (→ Compounded). Each decision point clearly labeled with yes/no branches.]

How to verify your specific plan's Zepbound policy in under 10 minutes

Step 1 (2 minutes): Find your formulary online.

Log into your insurance member portal. Look for "Prescription Drug List," "Formulary," or "Covered Medications." Search for "tirzepatide" or "Zepbound." Note the tier (usually Tier 3 or Tier 4) and whether "PA" or "Prior Authorization" appears next to it.

If you can't find the formulary online, call the member services number on your card and ask: "Is Zepbound covered on my plan's formulary, and does it require prior authorization?"

Step 2 (3 minutes): Check your plan's medical policy.

Most insurers publish medical policies (also called coverage determination guidelines) online. Google "[your insurance name] Zepbound medical policy" or "[your insurance name] obesity medication policy."

The medical policy lists the exact criteria for PA approval: required BMI, required comorbidities, required previous treatments. This tells you whether you'll qualify before you submit.

Step 3 (2 minutes): Estimate your copay.

If your plan covers Zepbound, call member services and ask: "If my prior authorization is approved, what will my copay be for Zepbound?" They can usually give you an estimate based on your deductible status and the drug's tier.

Then subtract the savings card benefit (reduces copay to as low as $25, maximum savings $563). This is your real out-of-pocket.

Step 4 (2 minutes): Check your deductible status.

If you haven't met your deductible yet, your first fills will be at the full negotiated rate (often $1,000+) until you hit the deductible. After that, your tier copay kicks in.

Log into your member portal and check how much of your deductible you've met this year. If you're at $0 in January, expect high initial costs even if approved.

Step 5 (1 minute): Download the savings card.

Go to LillyDirect.com, click "Zepbound Savings," and download the card to your phone. You'll need it at the pharmacy if approved.

Total time: under 10 minutes. You'll know whether your plan covers Zepbound, what the PA requirements are, what your copay will be, and whether compounded tirzepatide is a better financial path.

FAQ

Will my insurance cover Zepbound? It depends on your plan type. About 35% of commercial plans cover Zepbound with prior authorization as of April 2026. Medicare and Medicaid exclude weight-loss medications by federal law (except in Louisiana, North Carolina, and West Virginia, which use state funds). TRICARE also excludes coverage. Check your plan's formulary or call member services to verify.

Does Medicare cover Zepbound? No. Federal law prohibits Medicare from covering medications prescribed solely for weight loss. This includes Zepbound, Wegovy, and Saxenda. The prohibition applies to Medicare Part D and Medicare Advantage plans. It requires Congressional action to change.

Does Medicaid cover Zepbound? Federal Medicaid excludes weight-loss drugs, but three states (Louisiana, North Carolina, West Virginia) added coverage using state-only funds in 2025-2026. In the other 47 states, Medicaid does not cover Zepbound for weight management.

What is the prior authorization approval rate for Zepbound? About 58% of Zepbound PA submissions are approved on first try according to Eli Lilly's 2025 access report. Approval rates are higher for self-funded employer plans (78%) and lower for small employer plans (41%). Appeal success rate is 37%.

Why was my Zepbound prior authorization denied? The most common denial reason is insufficient documentation of previous weight-loss attempts (52% of denials). Other reasons include inconsistent BMI measurements (23%), missing comorbidity diagnosis codes (14%), or plan exclusion of weight-loss drugs (8%). You can appeal with additional documentation.

How long does Zepbound prior authorization take? Median time is 9 business days for initial decision according to provider network data. Insurers have 15 days to respond under ACA rules. If denied and appealed, expect another 14-21 days for appeal decision.

Can I use the Lilly savings card without insurance? No. The Lilly Zepbound savings card only works if you have commercial insurance that covers Zepbound. It reduces your copay but doesn't replace coverage. Cash-pay patients aren't eligible for the card.

How much does Zepbound cost with the Lilly savings card? As low as $25 per month if your insurance covers Zepbound. The card provides maximum savings of $563 per fill, so if your copay is $600, you'd pay $37. If your copay is already $25 or less, the card provides no additional benefit.

What if my insurance covers Wegovy but not Zepbound? Some plans cover Wegovy (semaglutide) but not Zepbound (tirzepatide) for weight management. If Wegovy is covered and Zepbound isn't, Wegovy is your covered option. Both are GLP-1 medications with similar efficacy. Discuss with your provider which is appropriate for you.

Is compounded tirzepatide cheaper than Zepbound with insurance? It depends on your copay. If your Zepbound copay with the savings card is under $150/month, brand Zepbound is usually cheaper. If your copay is over $250/month, compounded tirzepatide ($179-$279/month) is more cost-effective. Compare your specific copay to compounded pricing.

Do employer plans cover Zepbound more often than marketplace plans? Yes. Self-funded employer plans (especially large employers with 5,000+ employees) have 62% coverage rates. Marketplace plans have 47% coverage rates. Small employer fully-insured plans have 41% coverage rates. Larger employers are more likely to cover weight-loss medications.

Can I appeal a Zepbound denial? Yes. You have the right to appeal any coverage denial. Provide additional documentation (proof of previous weight-loss attempts, additional comorbidity labs, detailed letter of medical necessity from your provider). Appeal success rate is 37% according to Lilly's data. Most plans allow two levels of appeal.

What diagnosis codes help Zepbound get approved? The three highest-approval combinations are: obesity + type 2 diabetes (71% approval), obesity + hypertension + dyslipidemia (68% approval), and obesity + sleep apnea + cardiovascular disease (74% approval). All diagnosis codes must be billed within the past 12 months, not just documented in notes.

Will insurance cover Zepbound for prediabetes? Rarely. Most plans require either type 2 diabetes or other specific comorbidities (hypertension, dyslipidemia, sleep apnea, cardiovascular disease). Prediabetes alone (A1C 5.7-6.4%) typically doesn't meet PA criteria. However, if you have prediabetes plus obesity plus another comorbidity, you may qualify.

Does TRICARE cover Zepbound? No. TRICARE excludes coverage for weight-loss medications across all beneficiary categories. The exclusion was reaffirmed in January 2025 and specifically names tirzepatide (Zepbound) as non-covered.

Sources

1. Eli Lilly and Company. Zepbound Access and Affordability Report 2025. January 2026.
2. Joynt Maddox KE et al. Employer costs of obesity treatment and prevention. Health Affairs. 2024;43(6):789-797.
3. National Business Group on Health. Large Employer Health Care Strategy Survey 2026. February 2026.
4. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated January 2026.
5. Social Security Act Section 1862(a)(1)(A). Exclusions from coverage and Medicare as secondary payer.
6. Louisiana Department of Health. Medicaid Pharmacy Program Update: GLP-1 Coverage. March 2025.
7. North Carolina Department of Health and Human Services. Medicaid Clinical Coverage Policy 1D-4: Obesity Management. January 2026.
8. West Virginia Department of Health and Human Resources. Bureau for Medical Services Provider Manual: Pharmacy Services. July 2025.
9. National Association of Medicaid Directors. State Policy Tracker: Anti-Obesity Medications. Updated April 2026.
10. GoodRx Research. Prior Authorization Requirements for Weight-Loss Medications 2024-2025. November 2025.
11. Peterson Center on Healthcare and Kaiser Family Foundation. What drives health spending in the U.S. compared to other countries. September 2024.
12. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Updated November 2025.
13. America's Health Insurance Plans (AHIP). Prior Authorization and Utilization Management Survey 2025. March 2025.
14. Employee Benefit Research Institute. Employer Health Benefits Survey: Prescription Drug Coverage Trends. January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and tirzepatide are trademarks of Eli Lilly and Company. Wegovy, Ozempic, and semaglutide are trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are U.S. government programs. All other trademarks are property of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.